Navigation Links
Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
Date:6/25/2008

t of cancer and inflammatory diseases, RDEA436, in a human micro-dose pharmacokinetic study and have selected it as a development candidate.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our goals, including the expected properties and benefits of RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other compounds and the results of preclinical, clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, and costs associated with our drug discovery and development programs and business development activities. These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Caliper Life Sciences, Inc. ... tools and services for drug discovery and life ... the sale of Xenogen Biosciences Corporation ("XenBio"), a ... Taconic Farms, Inc. for approximately $11 million. ... Caliper,s acquisition of Xenogen Corporation in 2006. ...
(Date:12/14/2009)... The U.S. Food and Drug Administration (FDA) ... Suspension for the treatment of schizophrenia in adults, ... ) announced today. ZYPREXA RELPREVV, a long-acting intramuscular ... to four weeks. ,, Different from both oral ... allow for stable concentrations of the active drug ...
(Date:12/14/2009)... Inc. (OTC Bulletin Board: OXBT) today announced the expansion ... of Lt. Gen. Ronald R. Blanck, DO, U.S. Army ... Associates, a federal health services consulting firm based in ... now has nine members. ,, Dr. Blanck began his ... battalion surgeon in Vietnam. He retired 32 years later ...
Breaking Medicine Technology:Caliper Completes Strategic Sale of Small Animal Services Subsidiary to Taconic 2Caliper Completes Strategic Sale of Small Animal Services Subsidiary to Taconic 3Caliper Completes Strategic Sale of Small Animal Services Subsidiary to Taconic 4FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 2FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 3FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 4FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 5FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 6FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 7FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 8Oxygen Biotherapeutics, Inc. Expands Board of Directors 2Guayaki Delivers Powerful Rainforest Experience with Newest Yerba Mate Beverage Innovations 57354 1Guayaki Delivers Powerful Rainforest Experience with Newest Yerba Mate Beverage Innovations 57354 2Guayaki Delivers Powerful Rainforest Experience with Newest Yerba Mate Beverage Innovations 57354 3Critical Signal Technologies Acquires Link to Life to Grow Depth and Expertise in TeleHealth Personal Emergency Response and Medical Monitoring Syste 57351 1Critical Signal Technologies Acquires Link to Life to Grow Depth and Expertise in TeleHealth Personal Emergency Response and Medical Monitoring Syste 57351 2Critical Signal Technologies Acquires Link to Life to Grow Depth and Expertise in TeleHealth Personal Emergency Response and Medical Monitoring Syste 57351 3Hollis Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price 14094 1Hollis Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price 14094 2Hollis Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price 14094 3
... Cytopia,Limited (ASX: CYT) has commenced dosing patients in the ... its vascular disrupting agent (VDA), CYT997.,These studies will investigate ... with high unmet medical need and poor prognoses., ... cancer and have potential for,"blockbuster" sales in the treatment ...
... Children,s DNA, a Hint of a Mutation,s Ancestral African ... to replicate another group,s discovery of an important gene,associated ... particular,variant in DNA that may be more helpful in ... worldwide. The finding suggests that,the gene variant, identified in ...
Other Medicine Technology:Anti-Cancer Drug CYT997 Update 2Anti-Cancer Drug CYT997 Update 3Anti-Cancer Drug CYT997 Update 4Anti-Cancer Drug CYT997 Update 5Gene Hunters Fine-Tune Marker for Common Obesity Gene 2Gene Hunters Fine-Tune Marker for Common Obesity Gene 3
(Date:12/14/2009)... Kurth Krause, an aerospace engineer,for NASA, was giving ... moon, he,was confident that technology and science could ... was one thing that science couldn,t solve.,His wife ... dialysis machines,would keep her alive for awhile, she ... is 69 and is starting dialysis next month. ...
(Date:12/14/2009)... to scans performed in 2007 , , MONDAY, Dec. 14 ... to far more radiation than previously thought and in doses ... two new studies claim. , Based on the findings, reported ... Internal Medicine , the study authors, joined by Archives ... to limit radiation exposure to patients. , "CT has become ...
(Date:12/14/2009)... Decaf may also offer some protection, study finds, , , ... for people who can,t start their morning without a ... may decrease the risk of developing type 2 diabetes. ... that also found the more coffee you drink, the ... was associated with a 7 percent reduction in the ...
(Date:12/14/2009)... CHAPEL HILL -- Type 2 diabetes and obesity are ... Recently published studies suggested that insulin glargine (a synthetic ... be associated with a higher risk of certain cancers ... However, these studies were unable to control for important ... association. , On the other hand, a large ...
(Date:12/14/2009)... lead to better treatments for asthma, COPD, researchers say ... identified five genetic variants that influence lung function, a ... lung diseases. , The international team of researchers compared ... 2.5 million sites across the human genome in more ... team to the five common genetic variants associated with ...
Breaking Medicine News(10 mins):Health News:69-Year-Old Grandmother Needing A Lifesaving Kidney Transplant Finds a Miracle on the Internet: a 25-Year-Old Living Altruistic Organ Donor Stranger 2Health News:69-Year-Old Grandmother Needing A Lifesaving Kidney Transplant Finds a Miracle on the Internet: a 25-Year-Old Living Altruistic Organ Donor Stranger 3Health News:Studies Quantify Cancer Risks From CT Scans 2Health News:Studies Quantify Cancer Risks From CT Scans 3Health News:Studies Quantify Cancer Risks From CT Scans 4Health News:Coffee, Tea Might Stave Off Diabetes 2Health News:Coffee, Tea Might Stave Off Diabetes 3Health News:UNC scientists coordinate study of link between insulin use and cancer in people with diabetes 2
... Solta Medical, Inc. (Nasdaq: SLTM ), a ... it will release its financial results for the first quarter ... May 5, 2009. The Company will also host a ... 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss the ...
... N.C., April 27 Susan Brady of ... professionals in the nation to become certified by ... nonprofit organization that provides advocacy and education for ... demonstrated in-depth knowledge and expertise on best practices ...
... According to new research reported in the ... casei strain Shirota may ease symptoms of anxiety ... Thirty-nine patients with CFS received daily supplements of ... two months. Compared to the placebo group, ...
... at Telemedicine Conference in Las Vegas, Booth 1206 LAS ... Suisse AG (Fora Care,s Swiss sister company) announced today ... American Telemedicine Association (ATA) conference through April 28 at ... The veteran telemedicine companies are presenting at the ...
... following is being issued by American Stroke Association: , , ... It,s better to find out than miss out. Be aware ... and their side effects. Ask if your home should be modified ... doctor, nurse or therapist to clarify any unanswered questions or to ...
... April 27 Daily exposure to toxins in the ... adhesives, and insecticides, are creating a toxic load on ... and asthma. In light of increased awareness of our ... ) announced today the release of three ...
Other Medicine News:Health News:Solta Medical, Inc. Announces First Quarter 2009 Results Release Date and Conference Call 2Health News:MedThink Communications Account Director Among First to Receive CMPP Certification in Medical Publications Planning and Development 2Health News:New Study Shows Supplementing With Probiotics May Ease Anxiety 2Health News:Fora Care and Fora Care Suisse AG Launch Diabetes Telehealth Solution at ATA 2Health News:Fora Care and Fora Care Suisse AG Launch Diabetes Telehealth Solution at ATA 3Health News:15 Tips Caregivers Should Know After a Loved One Has Had a Stroke 2Health News:15 Tips Caregivers Should Know After a Loved One Has Had a Stroke 3Health News:Metametrix Announces New Toxic Effects Profiles to Help Combat Growing Concerns About Toxicity and Health 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: